- Modern view of the problem of recurrent hyperplastic processes of the endometrium
Modern view of the problem of recurrent hyperplastic processes of the endometrium
HEALTH OF WOMAN. 2020.7(153): 45-50; doi 10.15574/HW.2020.153.45
Tolstanova G. O.
Shupyk National Medical Academy of Postgraduate Education MH of Ukraine, Kiev
A review of current data on the problem of recurrent endometrial hyperplasia, presented in modern domestic and foreign literature, its place in the structure of gynecological morbidity, the impact on reducing fertility among women of childbearing age and the growth of cancer. The issues of existing classifications, their relevance and ease of use are considered. The main etiological factors and clinical and anamnestic factors of endometrial hyperplastic processes, prognostic influence of urogenital infections on endometrial pathology are highlighted. Possible mechanisms of pathogenesis are described, including disturbances of hormonal regulation, factors of local humoral and cellular immunity and molecular mechanisms of cellular regulation.
The important role of biomolecular markers in the pathogenesis of hyperplastic processes and the correspondence of their degree of activity to morphological changes of the endometrium, because understanding the basics of induction of cell growth, especially in tumor tissue transformation, is an integral part of a competent approach to the management of patients with hyperplasia. The role of genetic research to assess the risk of malignancy and, accordingly, the choice of conservative or operative treatment tactics is considered. Modern morphometric diagnostic criteria are presented.
Emphasis is placed on the need to collect endometrial biopsies under the control of a hysteroscope as the gold standard in the diagnosis of endometrial conditions. A separate role in the diagnosis at the present stage is given to immunohistochemical method; conducting not only histological examination of the removed endometrium, but also its receptor activity provides the ability to select the necessary pharmacological correction and predict the development of neoplastic changes. Variants of hormone therapy schemes of endometrial hyperplastic processes are described, and the order of their appointment, depending on the woman’s reproductive plans, concomitant diseases, age and constitutional features. Particular attention is paid to women with metabolic syndrome and the feasibility of including the correction of metabolic disorders in the treatment of such patients. The duration and frequency of observation of women during treatment are indicated.
The presented data demonstrate the lack of a clear algorithm in the tactics of diagnosis and treatment of recurrent hyperplastic processes, which determines the relevance of in-depth scientific study in this area.
Keywords: endometrial hyperplasia, recurrence, hysteroscopy, endometrial receptors
REFERENCES
1. Vdovychenko YP, Golyanovsky OV, Lopushan IV. 2012. Treatment of endometrial hyperplastic processes. Women's Health 6(30):1(31).
2. Vesich TL, Tuchkina IO, Guz IA, Blagoveshchensky RE. 2019. Biomolecular markers in the pathogenesis of hyperplastic processes of the endometrium. International Medical Journal 25;1(97):52-57.
3. Vizier KM, Dubinina VG. 2015. Risk factors for the development of atypical endometrial hyperplasia in women of reproductive age at the present stage. Women's Health 2(98):111-113. https://doi.org/10.15574/HW.2015.98.113
4. Clinical recommendations. Obstetrics and gynecologyю. ed. VN Serova, GT Dry. M, GEOTAR-Media. 2014: 748–757.
5. Kornienko SM. 2017. Hyperplastic processes of the endometrium in women in the late reproductive and premenopausal period: what affects relapses. Bulletin of social hygiene and health care in Ukraine. 2(72):39-47.
6. Levakov SA, Sheshukova NA, Bolshakova OV. 2017. Treatment of patients with endometrial hyperplasia. Problems of reproduction 2:33–36. https://doi.org/10.17116/repro201723233-36
7. Rogovskaya SI. 2000. Androgens and antiandrogens. Gynecology 2;2:47-51.
8. Sviridova NI, Tkachenko LV, Isaeva LV. 2017. Prevention of recurrence of endometrial hyperplasia in perimenopause. Bulletin of the Volgograd State Medical University 4(64):25-28. https://doi.org/10.19163/1994-9480-2017-4(64)-25-28
9. Tatarchuk TF, Efimenko OO, Migaychuk MV. 2010. Complex therapy of hyperplastic processes of the endometrium in women of late reproductive age. Medicines of Ukraine plus. 3(12):32-35.
10. Tatarchuk TF, Pedachenko NYu, Khominska ZB. 2014. Metabolic syndrome and hyperproliferative processes of the endometrium. Reproductive endocrinology 2(16):61-69. https://doi.org/10.18370/2309-4117.2014.16.61-69
11. Tolstanova GA. 2016. Actual aspects of the pathogenesis of chronic endometritis in patients with unrealized reproductive function. Collection of scientific works of NMAPE named after PL Shupyk 27; 2. Kyiv:156-163.
12. Tolstanova GO. 2018. Pathology of the endometrium in women with unrealized reproductive function: diagnosis and tactics of infertility treatment. Women's Health 5(131):108-110.
13. Tolstanova GO. 2016. Chronic endometritis – as a cause of female infertility: abstracts of the scientific-practical seminar with international participation "International and domestic standards of gynecological care" October 20, 2016, Kyiv. Collection of scientific works of NMAPE named after PL Shupyk 27; 2:.261. Kyiv
14. Von Wolf M, Stute P. 2017. Gynecological endocrinology and reproductive medicine. Per. with him., ed. EN Andreevoi. M, MEDpress-inform: 127–129; 378–380.
15. Chernukha GE, Dumanovskaya MR, Kogan EA. 2013. New possibilities for the treatment of endometrial hyperplasia. Obstetrics and gynecology 10:51–585.
16. Committee on Gynecologic Practice, Society of Gynecologic Oncology Committee opinion 631. Committee on Gynecologic Practice, Society of Gynecologic Oncology. Obstetrics & Gynecology 125; 5: 1272–1278. https://doi.org/10.1097/01.AOG.0000465189.50026.20; PMid:25932867
17. Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. 2013. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Human Reproduction 11;28:2966–2971. https://doi.org/10.1093/humrep/det320; PMid:23975691
18. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. 2010. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology 203;6:547.E1-547.E10. https://doi.org/10.1016/j.ajog.2010.07.037; PMid:20934679
19. Gültekin M, Dogan U, Aksan G. 2016. Management of endometrial hyperplasia. Minerva Ginecol. 62(5):433–445.
20. Hyun Jong Park, You Shin Kim, Tae Ki Yoon and Woo Sik Lee. 2016. Chronic endometritis and infertility. 43(4):185–192. https://doi.org/10.5653/cerm.2016.43.4.185; PMid:28090456 PMCid:PMC5234283
21. Kane SE, Hecht JL. Endometrial intraepithelial neoplasia terminology in practice: 4-year experience at a single institution. International Journal of Gynecological Pathology 31;2:160-165. https://doi.org/10.1097/PGP.0b013e318227505a; PMid:22317874
22. Lacey JV, Chia VM. 2009. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas. 63;1:39-44. https://doi.org/10.1016/j.maturitas.2009.02.005; PMid:19285814
23. Owings RA, Quick M. 2014. Endometrial intraepithelial neoplasia. Archives of Pathology & Laboratory Medicine. 138;4:484-491. https://doi.org/10.5858/arpa.2012-0709-RA; PMid:24678678
24. Raffone A, Travaglino A, Saccone G. 2019. Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? a systematic review and meta-analysis. Archives of Gynecology and Obstetrics 299;5:1233-1242. https://doi.org/10.1007/s00404-019-05103-1; PMid:30810881
25. Royal College of Obstetricians and Gynaecjlogists.Management of Endometrial Hyperplasia / RCOG / /BSGE Green-top Guidelaine. 2016, February. 67.
26. Simmons RS et al. 2011. The metabolic syndrome useful cocept or clinical tool Report of WHO Expert consultation. Diabetologia 1;53:151–158.
27. Travaglino A, Raffone A, Saccone G et al. 2018. Endometrial hyperplasia and the risk of coexistent cancer: who versus ein criteria. Histopathology. 74;5:676-687. https://doi.org/10.1111/his.13776; PMid:30347477
28. Usubutun A, Mutter GL, Saglam A et al. 2012. Reproducibility of endometrial intraepithelial neoplasia diagnosis is good, but influenced by the diagnostic style of pathologists. Modern Pathology 25;6:877-884. https://doi.org/10.1038/modpathol.2011.220; PMid:22301705
29. Vereide AB, Arnes M, Straume B, Maltau JM, Ørbo A. 2003. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecological Oncology. 91:526-533. https://doi.org/10.1016/j.ygyno.2003.07.002; PMid:14675671